Accelovance, a global contract research organization (CRO) focusing in oncology, vaccines, and general medicine has signed a merger agreement with Linical, a leading CRO based in Asia in the fields of oncology, immunology, and neurology.    The new company will offer clients even deeper oncology expertise, with combined scientific strength in both the early and late phases of clinical development. In addition, the company will provide significant leadership in many other therapeutic area...